STALICLA news
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDD
The Women in Data Science (WiDS) initiative promotes training and engagement of data scientists worldwide, regardless of gender, with an emphasis on supporting women working in the field. Women in Data Science congress is a unique event that brings together data scientists in the field of biomedicine in Barcelona. The event, which took place on September 28, 2022 at the Auditorium of th
The General Secretary of Innovation from the Spanish Ministry of Economy and Competitiveness has recently granted STALICLA DDS the status of innovative SME ("PYME innovadora"). The seal is an acknowledgement of STALICLA`s R&D activities and has been granted for a period of 3 years (valid till 16/09/2025)
STALICLA`s unique approach addresses a major weakness in the drug development process for Neurodevelopmental D
STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).
STALICLA`s unique approach addresses a major weak